

**INFORMATION DISCLOSURE  
CITATION**

Sheet 1 of 1

Attorney Docket No.  
**03848.00091**

Serial No.  
**TBA**

Applicant(s): **David MACK**

Filing Date: **July 25, 2001**

Group: **TBA**

**U.S. PATENT DOCUMENTS**

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

✓	<del>Lipshutz et al., "Using Oligonucleotide Probe Arrays To Access Genetic Diversity", BioTechniques, September 1995, Vol. 19, No. 3, pps. 442-447.</del>
✓	<del>Drmanac et al., "Gene Representing cDNA Clusters Defined by Hybridization of 57,419 Clones from Infant Brain Libraries with Short Oligonucleotide Probes", Genomics, October 1996, Vol. 37, No. 1, pps. 29-40.</del>
✓	<del>Sehena et al., "Parallel human genome analysis: Microarray-based Expression Monitoring of 1000 genes", Proc. Natl. Acad. Sci., USA, October 1996, Vol. 93, No. 20, pps. 10614-10619.</del>
✓	<del>Glynn et al., "B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression-profiling on microarrays", Immunological Reviews 2000, Vol. 176, pps. 216-246.</del>
✓	<del>Wang et al., "Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology", FEBS Letters, Vol. 445, 1999, pps. 269-273.</del>
✓	<del>Guo et al., "Identification of c-Myc Responsive Genes Using Rat cDNA Microarray", Cancer Research, Vol. 60, pps. 5922-5928, November 2000.</del>
	<del>Coller et al., "Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion", PNAS, Vol. 97, No. 7, pps. 3260-3265, March 2000.</del>
	<del>Sehena, BioEssays, Vol. 18, No. 5, 1996, pps. 427-431.</del>

EXAMINER


*C. M. / f*

DATE CONSIDERED

*December 3, 2002*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*\*Copies of references not provided at the time of this submission.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/911,856
Filing Date	July 25, 2001
First Named Inventor	David MACK
Group Art Unit	1631
Examiner Name	TBA
Attorney Docket Number	003848.00091

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CSM		Schena, M., <u>PNAS</u> , 93, pp. 10614-10619 (1996),	
CSM		Schena, M., <u>BioEssays</u> , 18 (5), pp. 427-431 (1996),	
CSM		Glynn et al., "B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays", <u>Immunological Reviews</u> 2000, Vol. 176, pp. 216-246,	
		Wang et al., "Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology", <u>FEBS Letters</u> , Vol. 445 (1999), pp. 269-273,	
		Guo et al., "Identification of c-Myc Responsive Genes Using Rat cDNA Microarray", <u>Cancer Research</u> , Vol. 60, pp. 5922-5928, November 1, 2000,	
		Coller et al., "Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion", <u>PNAS</u> , Vol. 97, No. 7, pp. 3260-3265, March 28, 2000,	
		Drmanac et al., "Gene-Representing cDNA Clusters Defined by Hybridization of 57,419 Clones from Infant Brain Libraries with Short Oligonucleotide Probes", <u>Genomics</u> , 01 October 1996, Vol. 37, No. 1, pp. 29-40,	
✓		Lipshutz et al., "Using Oligonucleotide Probe Assays to Access Genetic Diversity", <u>BioTechniques</u> , September 1995, Vol. 19, No. 3, pp. 442-47.	

Examiner  
Signature

C.M. / f

Date  
Considered

December 3, 2002

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PAPER No. 11

RECEIVED

APR 05 2002

TECH CENTER 1600/2900



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/911,856
Filing Date	July 25, 2001
First Named Inventor	David MACK
Group Art Unit	1631
Examiner Name	TBA
Attorney Docket Number	003848.00091

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
C3M		WO-95/19369 ✓	07-20-1995	Holt et al	p. 14; p. 37-47; claims	

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
C3M	✓	AMSON et al, "Isolation of 10 Differentially Expressed cDNAs in p53-induced Apoptosis: Activation of the Vertebrate Homologue of the <i>Drosophila</i> Seven in Absentia Gene, <i>Proc. Natl. Acad. Sci USA</i> , Vol. 93(9) (April 1996), pp. 3953-3957.	✓
	✓	BEAUDRY et al, "Therapeutic Targeting of the p53 Tumor Suppressor Gene", <i>Current Opinion in Biotechnology</i> , Vol. 7(7), (December 1996), pp. 592-600.	
	✓	ECHELARD et al, "Sonic Hedgehog, A Member of a Family of Putative Signaling Molecules, Is Implicated in the Regulation of CNS Polarity", <i>Cell</i> , Vol. 75, (December 1993), pp. 1417-1430.	
		European Search Report issued on May 28, 2002 in corresponding European Application EP 98 90 3639	

**RECEIVED**

JUL 2 2002

TECH CENTER 1600/2900

Examiner Signature	C. M. 1 f	Date Considered	December 3, 2002
-----------------------	-----------	--------------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PAPER No. 11